Recurrent B Acute Lymphoblastic Leukemia: Clinical Trials

15 trials for Recurrent B Acute Lymphoblastic Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 terminated, 4 withdrawn, 3 active not recruiting, 3 recruiting. 15 Phase 2, 9 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 215Terminated 5, Withdrawn 4, Active not recruiting 3, Recruiting 3
Phase 19Withdrawn 4, Terminated 3, Active not recruiting 1, Recruiting 1

Follow Recurrent B Acute Lymphoblastic Leukemia: new trials by email Literature Review of Recurrent B Acute Lymphoblastic Leukemia trials Research Report on Recurrent B Acute Lymphoblastic Leukemia

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2WithdrawnFred Hutchinson Cancer Center2025-04-012024-07-12
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Phase 1 / Phase 2WithdrawnChildren's Oncology Group2023-08-012023-09-01
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center42022-02-172025-08-11
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells
Phase 1 / Phase 2WithdrawnRoswell Park Cancer Institute2021-01-212022-01-28
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Phase 2RecruitingNational Cancer Institute (NCI)4612020-12-172026-11-12
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive
Phase 1 / Phase 2WithdrawnM.D. Anderson Cancer Center2019-05-152023-08-21
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia
Phase 2RecruitingNational Cancer Institute (NCI)842019-05-082026-11-12
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center532019-04-032026-05-13
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
ADCT-602 - Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center372018-08-242025-12-12
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Biospecimen Collection, Computed Tomography, Lumbar Puncture - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Active not recruitingECOG-ACRIN Cancer Research Group402018-08-132026-10-06
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
Blinatumomab, Cyclophosphamide, Cytarabine - Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia
Phase 2TerminatedM.D. Anderson Cancer Center62018-04-182022-11-04
Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia
Phase 2Active not recruitingM.D. Anderson Cancer Center402018-02-152026-08-10
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 2Active not recruitingChildren's Oncology Group802017-06-192026-10-01
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Cyclophosphamide, Cytarabine, Dasatinib - Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia
Phase 2TerminatedM.D. Anderson Cancer Center112015-07-152025-06-08
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Blinatumomab, Cyclophosphamide, Cytarabine - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Phase 1 / Phase 2RecruitingM.D. Anderson Cancer Center2762011-08-262026-07-15

Narrower conditions

Burkitt Lymphoma (15)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (4)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Disease Progression (1)  ·  Down Syndrome (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Neoplasm, Residual (1)

Broader conditions

DNA Virus Infections (15)  ·  Epstein-Barr Virus Infections (15)  ·  Hemic and Lymphatic Diseases (15)  ·  Herpesviridae Infections (15)  ·  Immune System Diseases (15)  ·  Immunoproliferative Disorders (15)  ·  Infections (15)  ·  Lymphatic Diseases (15)  ·  Lymphoma (15)  ·  Lymphoproliferative Disorders (15)  ·  Neoplasms (15)  ·  Neoplasms by Histologic Type (15)  ·  Tumor Virus Infections (15)  ·  Virus Diseases (15)  ·  Lymphoma, B-Cell (14)

Interventions

Vincristine (9)  ·  Cytarabine (8)  ·  Methotrexate (8)  ·  Cyclophosphamide (7)  ·  merphos (7)  ·  Dexamethasone (6)  ·  Biopsy (5)  ·  Calcium Dobesilate (5)  ·  Inotuzumab Ozogamicin (5)  ·  Mercaptopurine (5)  ·  Rituximab (5)  ·  Spinal Puncture (5)  ·  auricularum (5)  ·  dexamethasone 21-phosphate (5)  ·  dexamethasone acetate (5)

Sponsors

M.D. Anderson Cancer Center (8)  ·  Children's Oncology Group (2)  ·  National Cancer Institute (NCI) (2)  ·  ECOG-ACRIN Cancer Research Group (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Roswell Park Cancer Institute (1)

Countries

United States (14)  ·  Puerto Rico (4)  ·  Australia (1)  ·  Canada (1)

Top investigators

Elias Jabbour (3)  ·  Nitin Jain (2)  ·  Elias Jabbour, MD (1)  ·  Eunice S Wang (1)  ·  Jin S Im (1)  ·  Jordan Gauthier (1)  ·  Matthew A Kutny (1)  ·  Matthew J Wieduwilt (1)  ·  Maureen M O'Brien (1)  ·  Neil D Palmisiano (1)  ·  Nicholas Short, MD (1)  ·  Stacy L Cooper (1)

Results publications

PMID 35622074, PMID 41671463, PMID 38551807, PMID 28859185, PMID 29352703, PMID 35007127, PMID 37131217, PMID 37187201, PMID 37879077, PMID 38207208, PMID 38324336, PMID 39415930, PMID 41026957

NIH funding

U10CA180886 (3), P30CA016672 (2), U10CA180820 (1), U10CA180821 (1)